MoonLake Immunotherapeutics Files Q1 2025 10-Q
Ticker: MLTX · Form: 10-Q · Filed: May 12, 2025 · CIK: 1821586
| Field | Detail |
|---|---|
| Company | Moonlake Immunotherapeutics (MLTX) |
| Form Type | 10-Q |
| Filed Date | May 12, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, quarterly-report, pharmaceuticals
TL;DR
MoonLake Immunotherapeutics filed its Q1 2025 10-Q. Financials are in.
AI Summary
MoonLake Immunotherapeutics filed its 10-Q for the period ending March 31, 2025. The company, formerly Helix Acquisition Corp, is in the pharmaceutical preparations industry. Its principal executive offices are located in Zug, Switzerland. The filing covers the first quarter of 2025 and includes financial data from previous periods.
Why It Matters
This filing provides investors with the latest financial performance and operational updates for MoonLake Immunotherapeutics, crucial for assessing the company's current standing and future prospects.
Risk Assessment
Risk Level: low — This filing is a standard quarterly report and does not contain immediate, high-impact news.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the end of the financial quarter covered by the report.)
- 2025-05-12 — Filing Date (The date the report was officially submitted to the SEC.)
- 2024-12-31 — Previous Year End Date (Provides a comparison point to the current reporting period.)
Key Players & Entities
- MoonLake Immunotherapeutics (company) — Filer of the 10-Q
- Helix Acquisition Corp (company) — Former name of MoonLake Immunotherapeutics
- 20250331 (date) — End of the reporting period
- 20250512 (date) — Filing date
- 001-39630 (other) — SEC File Number
FAQ
What is the primary business of MoonLake Immunotherapeutics?
MoonLake Immunotherapeutics is in the Pharmaceutical Preparations industry, SIC code 2834.
When was the reporting period for this 10-Q filing?
The conformed period of report was March 31, 2025.
What was MoonLake Immunotherapeutics formerly known as?
The company was formerly known as Helix Acquisition Corp.
Where are MoonLake Immunotherapeutics' principal executive offices located?
The company's business address is Dorfstrasse 29, Zug, V8, 6300, Switzerland.
What is the SEC file number for MoonLake Immunotherapeutics?
The SEC file number is 001-39630.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 12, 2025 regarding MoonLake Immunotherapeutics (MLTX).